deltatrials
Active Not Recruiting OBSERVATIONAL NCT05613283

Primary Cervical Cancer Screening by Self-sampling HPV Test (PREVENT)

Sponsor: BeijingNewBiorayTechnologyCo.,Ltd.

Conditions Adenocarcinoma in Situ Atypical Glandular Cells Atypical Glandular Cells Not Otherwise Specified Atypical Glandular Cells, Favor Neoplastic Atypical Squamous Cells of Undetermined Significance Atypical Squamous Cells, Cannot Rule Out High-grade Squamous Intraepithelial Lesion Cervical Adenocarcinoma Cervical Cancer Cervical Intraepithelial Neoplasia Grade I Cervical Intraepithelial Neoplasia Grade II Cervical Intraepithelial Neoplasia, Grade III Cervical Squamous Cell Carcinoma Cervical Squamous Intraepithelial Lesion High-Grade Squamous Intraepithelial Lesions Human Papillomavirus Infection Low-Grade Squamous Intraepithelial Lesions Negative For Intraepithelial Lesion Or Malignancy
Updated 5 times since 2022 Last updated: Dec 19, 2023 Started: Nov 19, 2022 Primary completion: Jul 31, 2026 Completion: Aug 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Adenocarcinoma in Situ and Atypical Glandular Cells, this trial is ongoing. The trial is conducted by BeijingNewBiorayTechnologyCo.,Ltd. and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Jan 2024 · 11 months · monthly snapshotRecruiting~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotActive Not Recruiting

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Active Not Recruiting

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting

  3. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  4. Feb 2023 — Jan 2024 [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  5. Dec 2022 — Feb 2023 [monthly]

    Not Yet Recruiting

    First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeijingNewBiorayTechnologyCo.,Ltd.
  • Hangzhou Newhorizon Health Technology Co., Ltd.
  • Peking University People's Hospital
Data source: Peking University People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations